WC
BMY.RT

Westhampton Capital’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Westhampton Capital’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-11,150
Closed -$8K – 111
2020
Q4 		$8K Sell
11,150
-2,000
-15% -$4.26K 0.01% 103
2020
Q3 		$30K Hold
13,150
– – 0.02% 101
2020
Q2 		$47K Buy
+13,150
New +$47.4K 0.04% 104

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Westhampton Capital's BMY.RT Position: Q1 2021 in Review

Westhampton Capital sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 11,150 shares — an estimated $8K sold.

Westhampton Capital first reported a position in BMY.RT in Q2 2020 and held it in 3 quarters. The position peaked at $47K in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Westhampton Capital reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Westhampton Capital sold 11,150 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $8K.
  • Westhampton Capital first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q2 2020 and held it in 3 quarters.
  • Westhampton Capital's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $47K in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Westhampton Capital's 13F filing for Q1 2021, filed 11 May 2021.